Fluor has won an engineering, procurement and construction management contract for Novo Nordisk’s new $2bn diabetes active pharmaceutical ingredient (API) manufacturing facility in Clayton, North Carolina, US.

Novo Nordisk announced plans for the new facility in August last year and since then Fluor has been providing basic design services.

The company will now execute the complete scope of work.

Fluor life sciences and advanced manufacturing business president Juan Hernández said: “Fluor is honoured to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients.

“This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the south-east United States.”

"We look forward to continued strong cooperation for the success of this project."

The new 830,000ft² facility will produce life-saving medicines for use by patients across the globe.

Novo Nordisk senior vice-president Morten Nielsen said: “Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work.

“We look forward to continued strong cooperation for the success of this project.”

At peak construction, the facility is expected to create nearly 2,500 craft employees and subcontractor jobs and about 700 new jobs at the facility upon completion.

Construction on the facility is expected to be completed in mid-2019.